Arcutis’s Zoryve Succeeds In Second Phase III In Atopic Dermatitis

Immuno-dermatology specialist intends to submit the topical roflumilast to the US FDA during the first half of 2023, potentially adding an even larger indication to its approval for psoriasis.

Atopic dermatitis
Arcutis moves toward adding AD to the Zoryve label • Source: Shutterstock

With success in a second Phase III trial of its topical formulation of roflumilast in atopic dermatitis, Arcutis Biotherapeutics, Inc. moved closer to seeking a supplemental approval of Zoryve (roflumilast) in AD, which analysts said would be an even bigger market opportunity than the drug’s initial indication in plaque psoriasis.

Arcutis obtained US Food and Drug Administration approval of the topical phosphodiesterase-4 (PDE4) inhibitor for plaque psoriasis in July and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Pipeline Watch: Seven Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

More from R&D

Post-GLP-1 Patients Are Significant Opportunity, But Response Sees More

 

The company will move ahead in testing RDX-002 among overweight and obese patients coming off GLP-1s, but the CEO said antipsychotic-induced weight gain could represent a multibillion-dollar market.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By 

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.